Drug Profile
ASF 1097
Alternative Names: ASF-1097Latest Information Update: 08 Jul 2011
Price :
$50
*
At a glance
- Originator Astion Pharma A/S
- Class Anti-inflammatories; Antiacnes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acne vulgaris
Most Recent Events
- 08 Jul 2011 No development reported - Phase-I for Acne vulgaris in Denmark (Topical)
- 23 Jan 2007 Phase-I clinical trials in Acne vulgaris in Denmark (Topical)